Chris Sharp

Chris Sharp has extensive experience in the biomedical industry, particularly in regenerative biologics. Chris is currently the CEO of Skye Biologics Holdings, where they are focused on developing therapies for degenerative diseases and injuries. Prior to this, they served as the Chief Executive Officer of Human Regenerative Technologies, a company specializing in regenerative processing for medical applications. Chris was also the CEO of Skye Biologics Inc., where they provided tissue implants and biologics solutions to various medical specialties. Before that, they founded and served as CEO of Osprey Biomedical Corp, an allograft bio-implants company. Chris also held a position as Vice President of Sales and Business Development at Clearant Inc., a biotechnology company focused on pathogen inactivation technology. Chris began their career as a Director of Business Development at GenSci Regeneration Sciences Inc., where they worked on bioimplant therapeutic applications. Chris has a strong track record of successful business development, strategic partnerships, and revenue growth in the biomedical sector.

Chris Sharp, MBA, holds a Master of Business Administration (M.B.A.) degree in Finance and Marketing from EU Business School - Barcelona. Prior to that, they completed their Bachelor of Arts (BA) in Sociology/Anthropology from Carleton University. Chris also received a Secondary School Diploma (OSSD) from St. John's-Kilmarnock. In addition to their academic qualifications, Chris has a certification from the American Association of Tissue Banks for the Recovery, Processing, Storage, and Distribution of Musculoskeletal Tissue for Transplantation.